Skip to main content

Self-assembling Peptide Nanofibers Containing D-amino Acids for Tetrandrine Delivery

Buy Article:

$68.00 + tax (Refund Policy)

Self-assembling peptides have very recently emerged as a new class of drug vehicles, as they hold unique advantages such as good biocompatibility, design flexibility, and controllable nanotructure. In this work, we report a self-assembling peptide containing D-amino acids (Nap- GDFDFDYGRGD) as the carrier of anticancer drug tetrandrine. Tetrandrine is a bis-benzylisoquinoline alkaloid isolated from the root of Hang-Fang-Chi (Stephania tetrandra S. Moore). The D-peptides were employed in this study as they have shown stronger resistance against proteases than their Lcounterpart with natural L-amino acids. The Nap-GDFDFDYGRGD peptides can self-assemble into nanofibers, which are able to efficiently encapsulate tetrandrine. The drug-loaded nanofibers are capable of sustained release of tetrandrine and being internalized by the LoVo cancer cells. The cytotoxicity studies indicate that the tetrandrine-loaded nanofibers possess similar cytotoxicity to free tetrandrine against LoVo cancer cells and the Nap- GDFDFDYGRGD nanofibers can be used as a safe vehicle.

Keywords: D-Amino acid; drug carrier; drug delivery; peptide; self-assembly; tetrandrine

Document Type: Research Article

Publication date: 01 August 2015

More about this publication?
  • In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.

    The aim of this journal is to publish timely in-depth reviews as well as original papers in the field of signal transduction therapy. Thematic issues will also be published to cover selected areas of signal transduction therapy. Coverage of the field will include genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases.

    Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content